SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis.

The service branch will obligate $1,000 per vendor using research, development, test and evaluation funds for fiscal year 2024 and expects work to occur in the continental U.S. through Feb. 28, 2030.